Radar Caídas · 51/100 · Ready to research
51/100The chart uses daily closes adjusted by the available provider. There may be delays, gaps or differences versus the official source.
Links you can open and check yourself, most reliable first. Internal data-provider fetches are not listed here.
BillionToOne, Inc., a precision diagnostics company, quantifies biology to create molecular diagnostics. The company provides molecular counting platform, which is designed to detect and measure DNA molecules at the single-count level to help enhance disease detection.
The stock fell 35.6% and the most likely cause is this: Official filing with the SEC dated 5 August 2026.
This 80% is the confidence the model states about its own analysis after reviewing the sources.
Verified data: 7 of 10 checks have real data.
The market is pricing in an immediate and significant decline stemming from the earnings call and the sales activity reported on Form 144. The stock fell ~38.9% during the August 6 trading session and -35.6% over 48 hours, indicating that investors are reacting to the news with a short-term decline in value that implies a lasting impact on the business.
!! Clearly exaggerated
A 38.89% drop in price in one day despite the absence of any financial charge or contract loss disclosed in the filings dated August 5, 2026. Objective data: reported revenue up 64% (according to call summaries), total reported cash of $537,450k and net cash of $393,263k, positive operating cash flow of $37.4M, and positive free cash flow based on reported data. There is no evidence of a fine, bankruptcy, or loss of a major client; therefore, the magnitude of the decline is not supported by a quantified economic impact in the available official documents.
The quantifiable direct economic impact of the information disclosed in recent earnings reports and filings is estimated to be low (with no reported monetary charges or loss of contracts), so the drop of ~39 percentage points far exceeds that estimated impact, indicating a strong overreaction.
Management confirms in official communications (filings or press releases) that it is maintaining or improving the forecasts published by the company and explains the trading activity of insiders; furthermore, net buying by institutional investors or executives is observed in the days that follow.
There are no additional charges or downward revisions to forecasts over the next 1–4 weeks; the company releases details clarifying the transaction, and the reported sales are absorbed by the market.
Additional negative information emerges in filings (charges, regulatory investigations, or downward revisions to forecasts), or selling pressure from Form 144 filings results in a sustained increase in supply.
Horizon: 1–4 weeks
Horizon: 1–4 weeks
Horizon: 1–3 weeks
No verifiable comparable cases were saved for this page.
The score is computed by Python code from objective data, not by the AI model, and it does not change after the qualitative research.
Values used by this framework's Python scoring engine at detection time. Only indicators the data source could confirm are shown.
Why some numbers are coloured and others stay grey
Colour repeats what the sign already says, at three intensities depending on how far the value is from zero. It is never the only signal.
Everything whose sign is not good or bad on its own stays grey: valuation (a low P/E can be a bargain or a trap, and almost every company here has just fallen), debt, size, insider ownership and short interest. Those are shown as-is, without the site taking a view.
The ~38% drop following the earnings release and the earnings call on August 5 appears to be an overreaction by the market: the company reported 64% revenue growth and shows a substantial positive net cash balance according to its financial statements, with no quantified charges in the filings dated August 5, 2026.
Release of second-quarter 2026 results and earnings call on August 5, 2026, followed by media coverage that questioned the valuation and sales activity/sales orders (Form 144) reported in the filings from August 3–5. | Next month
Can BillionToOne (BLLN) Justify Its Price On Earnings And Reaffirmed 2026 Guidance? · 6 August 2026
We don't judge whether it's good or bad news: compare it against the real return since detection in the table below.